Zacks: Brokerages Expect Catalent, Inc. (NYSE:CTLT) Will Post Quarterly Sales of $1.16 Billion

Wall Street brokerages expect Catalent, Inc. (NYSE:CTLT) to report $1.16 billion in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Catalent’s earnings, with the lowest sales estimate coming in at $1.14 billion and the highest estimate coming in at $1.20 billion. Catalent posted sales of $910.80 million during the same quarter last year, which would indicate a positive year over year growth rate of 27.4%. The firm is expected to issue its next quarterly earnings results on Tuesday, February 1st.

According to Zacks, analysts expect that Catalent will report full year sales of $4.72 billion for the current year, with estimates ranging from $4.65 billion to $4.82 billion. For the next financial year, analysts forecast that the business will post sales of $5.18 billion, with estimates ranging from $4.99 billion to $5.33 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Catalent.

Catalent (NYSE:CTLT) last released its earnings results on Monday, November 1st. The company reported $0.71 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.06. Catalent had a return on equity of 14.64% and a net margin of 13.68%. During the same period last year, the company earned $0.33 earnings per share.

Several equities analysts recently commented on CTLT shares. Royal Bank of Canada upped their target price on Catalent from $145.00 to $155.00 and gave the company an “outperform” rating in a research note on Wednesday, November 3rd. KeyCorp upped their target price on Catalent from $142.00 to $155.00 and gave the company an “overweight” rating in a research note on Tuesday, August 31st. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating and set a $142.00 price target for the company. in a research note on Friday, October 29th. Morgan Stanley upped their price target on Catalent from $147.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 3rd. Finally, Bank of America upped their price target on Catalent from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, August 31st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $149.89.

In related news, SVP Kay A. Schmidt sold 825 shares of the stock in a transaction dated Friday, August 27th. The stock was sold at an average price of $131.13, for a total value of $108,182.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Thomas P. Castellano sold 2,093 shares of the stock in a transaction dated Friday, August 27th. The shares were sold at an average price of $131.13, for a total value of $274,455.09. The disclosure for this sale can be found here. Insiders sold 223,652 shares of company stock valued at $29,281,740 in the last ninety days. Company insiders own 0.53% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of CTLT. Selective Wealth Management Inc. acquired a new stake in Catalent during the third quarter valued at approximately $27,000. Assetmark Inc. acquired a new stake in Catalent during the third quarter valued at approximately $34,000. Berman Capital Advisors LLC raised its stake in Catalent by 131.2% during the second quarter. Berman Capital Advisors LLC now owns 326 shares of the company’s stock valued at $35,000 after buying an additional 185 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in Catalent during the third quarter valued at approximately $40,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Catalent during the second quarter valued at approximately $43,000. 97.63% of the stock is owned by hedge funds and other institutional investors.

Catalent stock traded up $1.73 during trading on Thursday, hitting $129.59. The company’s stock had a trading volume of 753,363 shares, compared to its average volume of 945,928. The stock has a market capitalization of $22.18 billion, a price-to-earnings ratio of 40.88, a P/E/G ratio of 2.18 and a beta of 1.32. The stock’s fifty day moving average is $131.59 and its 200 day moving average is $121.17. Catalent has a 1-year low of $91.87 and a 1-year high of $142.64. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.02 and a current ratio of 3.59.

About Catalent

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Read More: What is a Special Dividend?

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.